1. Home
  2. NMZ vs ANL Comparison

NMZ vs ANL Comparison

Compare NMZ & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Municipal High Income Opportunity Fund $0.01 par value per share

NMZ

Nuveen Municipal High Income Opportunity Fund $0.01 par value per share

N/A

Current Price

$9.09

Market Cap

1.2B

Sector

Finance

ML Signal

N/A

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

N/A

Current Price

$15.99

Market Cap

998.8M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
NMZ
ANL
Founded
2003
2004
Country
United States
Singapore
Employees
N/A
N/A
Industry
Finance/Investors Services
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
998.8M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
NMZ
ANL
Price
$9.09
$15.99
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
★ $29.50
AVG Volume (30 Days)
★ 1.5M
181.7K
Earning Date
01-01-0001
08-14-2026
Dividend Yield
★ 5.08%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$243.83
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.69
$0.88
52 Week High
$10.77
$17.25

Technical Indicators

Market Signals
Indicator
NMZ
ANL
Relative Strength Index (RSI) 42.80 57.29
Support Level $8.70 $14.70
Resistance Level $10.52 $17.10
Average True Range (ATR) 0.18 1.18
MACD 0.04 -0.10
Stochastic Oscillator 51.66 70.03

Price Performance

Historical Comparison
NMZ
ANL

About NMZ Nuveen Municipal High Income Opportunity Fund $0.01 par value per share

Nuveen Municipal High Income Opp Fund is a diversified, closed-end management investment company. The Fund's primary investment objective is to provide high current income exempt from regular federal income tax. The Fund's secondary investment objective is to seek an attractive total return consistent with its primary objective.

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

Share on Social Networks: